List of Figures
Figure 1: Global Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 2: Global Estimated number of Cancer incidences and prevalent cases (all ages, in millions), Year 2020
Figure 3: Global Cancer related number of deaths (all ages, in thousand's), Year 2020
Figure 4: Global Estimated number of Diabetes prevalent cases (adults (20-79), in millions), Year 2021
Figure 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
Figure 6: Global Aged Population (Above 65), 2015-20 (% of total Population)
Figure 7: Global Aged Population (Above 65), By Country, 2020 (% of total Population)
Figure 8: Global Medical Spending in 2020, By Region, (% of Total)
Figure 9: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
Figure 10: Global Expected Healthcare Industry Outlook
Figure 11: Regional Expected Healthcare Industry Growth Rate By Year 2024
Figure 12: Global Generic Injectables Market- By Molecule Type Market Share, 2021 & 2027
Figure 13: Global Generic Injectables Market- By Small Molecule, By Value (USD Billion), 2017-2027
Figure 14: Global Generic Injectables Market- By Large Molecule, By Value (USD Billion), 2017-2027
Figure 15: Global Generic Injectables Market - By Therapeutic Area Market Share, 2021 & 2027
Figure 16: Global Generic Injectables Market- By Oncology, By Value (USD Billion), 2017-2027
Figure 17: Global Generic Injectables Market- By Anti-infectives, By Value (USD Billion), 2017-2027
Figure 18: Global Generic Injectables Market- By Cardiovascular, By Value (USD Billion), 2017-2027
Figure 19: Global Generic Injectables Market- By Diabetes, By Value (USD Billion), 2017-2027
Figure 20: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
Figure 21: Global Generic Injectables Market- By Container Market Share, 2021 & 2027
Figure 22: Global Generic Injectables Market- By Vials, By Value (USD Billion), 2017-2027
Figure 23: Global Generic Injectables Market- By Ampoules, By Value (USD Billion), 2017-2027
Figure 24: Global Generic Injectables Market- By Pre-filled Syringes, By Value (USD Billion), 2017-2027
Figure 25: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
Figure 26: Global Generic Injectables Market- By Region Market Share, 2021 & 2027
Figure 27: North America Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 28: Prevalence of Cardiovascular Diseases in North America, (in million), 2015-2019
Figure 29: Cancer prevalence in North America (in million), Year 2020
Figure 30: Prevalence of Multiple Sclerosis in North America, (in 1000’s), 2015-2019
Figure 31: North America Diabetes Prevalence, By Country, 2020 (% of Population Aged 20-79)
Figure 32: North America Diabetes-related health expenditure per person, USD (Year 2021)
Figure 33: North America Current health expenditure per capita (current USD), 2014-18
Figure 34: North America Population ages 65 and above (% of total Population), 2016-20
Figure 35: North America Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 36: North America Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 37: North America Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 38: Market Opportunity Chart of North America Generic Injectables Market- By Country, By Value (Year-2027)
Figure 39: North America Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 40: United States Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 41: Prevalence of Cardiovascular Diseases in United States, (in million), 2015-2019
Figure 42: Prevalence of Multiple Sclerosis in United States, (in 1000’s), 2016-2019
Figure 43: Cancer prevalence in United States (in million), Year 2020
Figure 44: United States Current health expenditure per capita (current USD), 2016-2020
Figure 45: United States Population aged 65 and above (% of total Population), 2016-20
Figure 46: Estimated people with diabetes in United States (in millions), 2021-2045
Figure 47: United States Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 48: United States Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 49: United States Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 50: Canada Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 51: Prevalence of Cardiovascular Diseases in Canada, (in million), 2015-2019
Figure 52: Estimated number of Cancer Prevalent cases in Canada, 2020
Figure 53: Prevalence of Multiple sclerosis in Canada, (in 1000’s), 2016-2019
Figure 54: Canada Current health expenditure per capita (current USD), 2017-2021
Figure 55: Canada Population aged 65 and above (% of total Population), 2016-20
Figure 56: Estimated people with diabetes in Canada (in millions), 2021-2045
Figure 57: Canada Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 58: Canada Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 59: Canada Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 60: Europe Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 61: Europe Prevalence of Cardiovascular Diseases (in Million), 2015-2019
Figure 62: Prevalence of Osteoarthritis Diseases in Europe, (in Million), 2015-2019
Figure 63: Europe estimated number of Cancer prevalence (all ages, in Million), Year 2020
Figure 64: Europe Prevalence of Multiple Sclerosis, 2016-2019 (In 1000’s)
Figure 65: Europe Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
Figure 66: Europe Current health expenditure per capita (current USD), 2015-18
Figure 67: Total expenditure on health per capita in European countries (in USD PPP), 2019
Figure 68: Population ages 65 and above (% of total Population) in European Countries, 2020
Figure 69: Europe Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 70: Europe Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 71: Europe Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 72: Market Opportunity Chart of Europe Generic Injectables Market- By Country, By Value (Year-2026)
Figure 73: Europe Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 74: Germany Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 75: Prevalence of Cardiovascular Diseases in Germany, (in million), 2015-2019
Figure 76: Estimated people with diabetes in Germany (in millions), 2021-2045
Figure 77: Prevalence of Multiple Sclerosis in Germany, (in 1000’s), 2016-2019
Figure 78: Germany Current health expenditure per capita (current USD), 2015-2019
Figure 79: Germany Population aged 65 and above (% of total Population), 2016-20
Figure 80: Germany, Estimated percentage of prevalent Cancer cases, 2020
Figure 81: Germany Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 82: Germany Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 83: Germany Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 84: United Kingdom Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 85: Estimated people with diabetes in United Kingdom (in millions), 2021-2045
Figure 86: United Kingdom, Estimated percentage of prevalent Cancer cases, 2020
Figure 87: Prevalence of Multiple Sclerosis in United Kingdom, (in 1000’s), 2015-2019
Figure 88: United Kingdom Current health expenditure per capita (current USD), 2015-2019
Figure 89: United Kingdom Population aged 65 and above (% of total Population), 2016-20
Figure 90: Prevalence of Cardiovascular Diseases in United Kingdom, (in million), 2015-2019
Figure 91: United Kingdom Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 92: United Kingdom Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 93: United Kingdom Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 94: France Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 95: Estimated people with diabetes in France (in millions), 2021-2045
Figure 96: France, Estimated percentage of prevalent Cancer cases, 2020
Figure 97: Prevalence of Multiple Sclerosis in France, (in 1000’s), 2015-2019
Figure 98: France Current health expenditure per capita (current USD), 2015-2019
Figure 99: France Population aged 65 and above (% of total Population), 2016-20
Figure 100: Prevalence of Cardiovascular Diseases in France, (in million), 2015-2019
Figure 101: France Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 102: France Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 103: France Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 104: Italy Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 105: Estimated people with diabetes in Italy (in millions), 2021-2045
Figure 106: Italy, Estimated percentage of prevalent Cancer cases, 2020
Figure 107: Prevalence of Multiple Sclerosis in Italy, (in 1000’s), 2015-2019
Figure 108: Italy Current health expenditure per capita (current USD), 2015-2019
Figure 109: Italy Population aged 65 and above (% of total Population), 2016-20
Figure 110: Prevalence of Cardiovascular Diseases in Italy, (in million), 2015-2019
Figure 111: Italy Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 112: Italy Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 113: Italy Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 114: Asia Pacific Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 115: Prevalence of Cardiovascular Diseases in Asia Pacific, (in million), 2015-2019
Figure 116: Cancer prevalence in Asia Pacific (in thousands), Year 2020
Figure 117: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
Figure 118: Asia Pacific Current health expenditure per capita (current USD), 2014-18
Figure 119: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
Figure 120: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
Figure 121: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 122: Asia Pacific Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 123: Asia Pacific Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 124: Asia Pacific Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 125: Market Opportunity Chart of Asia Pacific Generic Injectables Market- By Country, By Value (Year-2026)
Figure 126: Asia Pacific Generic Injectables Market- By Country Market Share, 2021 & 2027
Figure 127: China Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 128: Estimated people with diabetes in China (in millions), 2021-2045
Figure 129: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 130: Estimated number of Cancer prevalent cases in China (all ages, in 1000’s), Year 2020
Figure 131: China Current health expenditure per capita (current USD), 2015-2019
Figure 132: China Population aged 65 and above (% of total Population), 2016-20
Figure 133: China Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 134: China Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 135: China Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 136: Japan Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 137: Estimated people with diabetes in Japan (in millions), 2021-2045
Figure 138: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 139: Estimated number of Cancer prevalent cases in Japan (all ages, in 1000’s), Year 2020
Figure 140: Japan Healthcare Expenditure Outlook (%)
Figure 141: Japan Population aged 65 and above (% of total Population), 2016-20
Figure 142: Japan Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 143: Japan Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 144: Japan Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 145: India Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 146: Estimated people with diabetes in India (in millions), 2021-2045
Figure 147: Estimated number of Cancer prevalent cases in India (all ages, in 1000’s), Year 2020
Figure 148: Prevalence of Multiple Sclerosis in India, (in 1000’s), 2016-2019
Figure 149: Estimated value of public health spending in India (from 2017-20, in billions USD)
Figure 150: India Population aged 65 and above (% of total Population), 2016-20
Figure 151: Prevalence of Cardiovascular Diseases in India, (in million), 2015-2019
Figure 152: India Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 153: India Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 154: India Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 155: Australia Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
Figure 156: Estimated people with diabetes in Australia (in millions), 2021-2045
Figure 157: Estimated number of Cancer prevalent cases in Australia (all ages, in 1000’s), Year 2020
Figure 158: Prevalence of Multiple Sclerosis in Australia, (in 1000’s), 2016-2019
Figure 159: Australia Current health expenditure per capita (current USD), 2015-2019
Figure 160: Australia Population aged 65 and above (% of total Population), 2016-20
Figure 161: Prevalence of Cardiovascular Diseases in Australia, (in million), 2015-2019
Figure 162: Australia Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
Figure 163: Australia Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 164: Australia Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
Figure 165: Market Attractiveness Chart of Global Generic Injectables Market- By Molecule Type (Year-2027)
Figure 166: Market Attractiveness Chart of Global Generic Injectables Market- By Therapeutic Area (Year-2027)
Figure 167: Market Attractiveness Chart of Global Generic Injectables Market- By Container (Year-2027)
Figure 168: Market Attractiveness Chart of Global Generic Injectables Market- By Region (Year-2027)
Figure 169: Global Generic Injectables company market share (%), 2021
Figure 170: Market share in generic injectables in US (by value), 2021
Figure 171: Market share in generic injectables in US (by volume), 2021
Figure 172: Pfizer Inc. Annual Sales Revenue, 2016-2020 (USD Million)
Figure 173: Pfizer Inc. Net Income, 2016-2020 (USD Million)
Figure 174: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 175: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 176: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 177: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 178: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 179: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 180: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 181: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 182: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 183: Baxter International Sales Revenues, 2016-2020 (USD Million)
Figure 184: Baxter International Net Income, 2016-2020 (USD Million)
Figure 185: Baxter International Sales Revenue Split, By Business Segment (%), FY2020
Figure 186: Baxter International Sales Revenue Split, By Geography Segment (%), FY2020
Figure 187: Fresenius SE & Co KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 188: Fresenius SE & Co KGaA Net Income, 2016-2020 (USD Million)
Figure 189: Fresenius SE & Co KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 190: Fresenius SE & Co KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 191: Amneal Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 192: Amneal Pharmaceuticals Net Income, 2016-2020 (USD Million)
Figure 193: Amneal Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 194: Amneal Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 195: Hikma Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 196: Hikma Pharmaceuticals Net Income, 20016-2020 (USD Million)
Figure 197: Hikma Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 198: Hikma Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 199: Gland Pharma Annual Sales Revenue (USD Million), 2017-2020
Figure 200: Gland Pharma Net Income (USD Million), 2017-2020
Figure 201: Gland Pharma Sales Revenue, By Business Segment (%), FY2020
Figure 202: Gland Pharma Sales Revenue, By Geographical Segment (%), FY2020
Figure 203: Teva Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
Figure 204: Teva Pharmaceuticals Net Income, 2016-2020 (USD Million)
Figure 205: Teva Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
Figure 206: Teva Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
Figure 207: Nichi-iko Pharmaceutical Sales Revenues, 2016-2020 (USD Million)
Figure 208: Nichi-iko Pharmaceutical Net Income, 2016-2020 (USD Million)
Figure 209: Nichi-iko Pharmaceutical Sales Revenue Split, By Business Segment (%), FY2020
Figure 210: Nichi-iko Pharmaceutical Sales Revenue Split, By Geography Segment (%), FY2020
